Open-label, phase IIIb, multicenter, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET).
Authors | |
---|---|
Year of publication | 2013 |
Type | Appeared in Conference without Proceedings |
Citation |
Authors | |
---|---|
Year of publication | 2013 |
Type | Appeared in Conference without Proceedings |
Citation |